Inova Diagnostics, Inc.

Leiden University Medical Center

Michael Mahler

Jan Wouter Drijfhout

Leendert Adrianus Trouw

René Toes

Tom Huizinga

Peter Van Veelen

The present disclosure relates to the use of anti-PAD IgA as a clinical biomarker for diagnostic and prognostic information in rheumatoid arthritis (RA) patients. The disclosure further provides methods and compositions for the detection anti-PAD IgA in a biological sample.

Compositions and methods for diagnosing and assessing rheumatoid arthritis

The present disclosure relates to the field of molecular biology and more specifically to methods for detecting anti-carbamylated protein (anti-CarP) antibodies in the serum of rheumatoid arthritis (RA) patients.

Compositions and methods for the diagnosis of rheumatoid arthritis

Provided is a method for increasing the specificity of an antibody-based test to help in the diagnosis of autoimmune diseases by contacting a subject's sample with a blocking antigen prior to testing that is capable of binding to any interfering antibody present in the sample. More specifically, a method for increasing specificity of an antibody-based autoimmune disease assay comprising the steps of providing a sample from a subject, contacting the sample with a DFS70 derived antigen, reacting the sample with an autoimmune disease target and detecting antibodies to the autoimmune disease target is disclosed.

Growing community of inventors

Bad Neuenahr, Germany

Michael Mahler